$RGBP$ - Senior Research Director Dr. Christine Ichim presented data demonstrating NR2F6, a new "Drug Target" at The Annual Meeting of The American Society of Hematology (NYSE:ASH) Dec 6, 2014 in San Diego California.
A " Drug Target" is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. It is essential in development and maintenance of leukemia and myelodysplastic syndrome. The work entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage".
"Acceptance of this work by the scientific committee of the American Society of Hematology (ASH) for presentation provides a strong signal the scientific community is supportive of this novel area of investigation," said Dr. Thomas Ichim PhD, the Company's Chief Scientific Officer. "We believe that the data presented was well received by industry and academic groups, giving the company excellent exposure, and opportunities to network and collaborate with some of the world's top physicians, scientists and pharmaceutical companies."
The ASH Annual Conference is the premier meeting discussing normal and malignant blood disorders. There were more than 18,000 physicians and scientists, as well as more than 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations from 50 states and nearly 100 countries outside the United States1 in attendance.
See More: http://finance.yahoo.com/news/regen-biopharma-presented-novel-therapeutic-133000659.html
$RGBP$ is still in ongoing comments with the FDA for clearance and approval of their new drug - dCellVax. dCellVax has proven to kill cancerous tumors in Lab Animals. It is a stem cell treatment/drug that has none of the ill/harsh side effects like "Chemo" Once All of the FDA Comments Are Addressed, the Company Aims to Initiate Gene Silencing Immunotherapy for Metastatic Breast Cancer Patients
$RGBP$ is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
For more information, please contact me.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.